January 15th 2025
Building on a previous report that revealed corrupt business practices among the big 3 PBMs, a second interim report finds that PBMs heightened prices for important specialty generic drugs to increase their profit margins.
Study: Mortality Rate Higher for US Rural Residents
October 27th 2020A recent study found that the US rural mortality penalty is wide and further expanding, which applies to the rural population overall, or all racial/ethnic groups combined, and for non-Hispanic whites, non-Hispanic blacks, and Hispanics individually.
Study: Modifiable Health Risks Linked to More Than $730 Billion in US Health Care Costs
October 2nd 2020A study published in The Lancet Public Health found that modifiable health risks, such as obesity, high blood pressure, and smoking, were linked to more than $730 billion in health care spending in the United States in 2016.
Significant Provider Relief Fund Updates: Expanded Eligibility and a Reporting Update
September 11th 2020The terms of participation in the phase 2 round of the Provider Relief Fund created an unintended exclusion for pharmacies that primarily serve Medicaid/Children’s Health Insurance Program patients.
Specialty Pharmacies Improve Patient Outcomes, Minimize Costs to Health Care System
September 9th 2020The goals of specialty pharmacy programs are to reduce or delay progression of the disease, improve patient outcomes, enhance patients’ quality of life, keep patients in the workforce longer, and decrease total health care costs.
Study: Medicare Beneficiaries Visit Pharmacies Much More Often than Primary Care Offices
August 3rd 2020The investigators noted that the shift toward value-based care has placed a greater emphasis on preventive care and chronic disease management services as delivered by multidisciplinary health care teams.
Pharmacists Express Concern Over Lack of Provider Status in Proposed Stimulus Package
July 28th 2020As legislators debate the next stimulus package, pharmacists are expressing dismay that the current language does not include designating pharmacists as providers under Medicare Part B for COVID-19 testing and immunization.